Effect of adjuvant radiotherapy on cancer specific survival of patients with high grade urinary bladder cancer after bladder sparring surgery

Authors

DOI:

https://doi.org/10.26641/2307-5279.25.1.2021.231341

Abstract

External beam radiotherapy is an important element of the organ sparring treatment of muscle invasive bladder cancer. Multimodal approach to treating selected patients can yield satisfactory long term oncological outcomes, preservation of adequate function of urinary bladder, acceptable quality of life and low rate of salvage cystectomies in case of cancer progression.

Purpose. To determine the effect of conventional adjuvant radiotherapy (ART) delivered with linear accelerator on cancer specific survival (CSS) of patients with high grade bladder cancer (HGBCa) after bladder sparring surgery.

Materials and methods. We retrospectively assessed the treatment outcomes of 325 HGBCa patients after bladder sparring surgery with or without ART on linear accelerator Oncor Impression Plus with total dose 62 Gy (58-70 Gy) and daily fraction of 2 Gy. Kaplan-Meier statistical method was used to compare the survival outcomes between groups of patients.

Results. Radiotherapy after bladder sparring surgery was delivered to 101 (31.1%) patients. Salvage cystectomy in case of cancer progression after combined therapy was performed on 12 (11.9%) patients. Only patients with stage рТ4N0 demonstrated improvements in CSS after ART (р=0,041), with 5-year survival 16% vs. 10%. In patients of other cancer stages the improvement in CSS were not determined. Five-year CSS for HGBCa patients stage I, II, III, IV and N+ after bladder sparring surgery with and without ART was 50% vs. 36%, 20% vs. 33%, 31% vs. 29%, 16% vs. 10%, and 13% vs. 14%.

Conclusion. External beam radiotherapy after bladder sparring surgery in patients with high grade bladder cancer improved cancer specific survival in patients with stage рТ4N0 (р=0,041), 5-year survival was 16% vs. 10% for patients without radiotherapy. In patients of other stages of bladder cancer adjuvant radiotherapy did not demonstrate the benefits for survival.

References

Ploussard G., Daneshmand S., Efstathiou J.A., Herr H.W., James N.D., Rodel C.M. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014. Vol. 66, No. 1. P. 120–137.

Giacalone N.J., Shipley W.U., Clayman R.H., Niemierko A., Drumm M., Heney N.M. et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017. Vol. 71, No. 6. P. 952–960.

Zhang S., Yu Y.H., Zhang Y., Qu W., Li J. Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application. Am J Cancer Res. 2015. Vol. 5, No. 2. P. 854–868.

Foroudi F., Wilson L., Bressel M., Haworth A., Hornby C., Pham D. et al. A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol. 2012. Vol. 7. P. 111.

Guckenberger M., Richter A., Krieger T., Wilbert J., Baier K., Flentje M. Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes? Radiother Oncol. 2009. Vol. 93, No. 2. P. 259–265.

Welsh J.S., Patel R.R., Ritter M.A., Harari P.M., Mackie T.R., Mehta M.P. Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat. 2002. Vol. 1, No. 4. P. 311–316.

Lee C.Y., Yang K.L., Ko H.L., Huang R.Y., Tsai P.P., Chen M.T. et al. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Radiat Oncol. 2014. Vol. 9. P. 213.

Froehner M., Brausi M.A., Herr H.W., Muto G., Studer U.E. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol. 2009. Vol. 56, No. 3. P. 443–454.

Heberling U., Koch R., Hubler M., Baretton G.B., Hakenberg O.W., Wirth M.P. et al. Gender and Mortality after Radical Cystectomy: Competing Risk Analysis. Urol Int. 2018. Vol. 101, No. 3. P. 293–299.

Williams S.B., Kamat A.M., Chamie K., Froehner M., Wirth M.P., Wiklund P.N. et al. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol. 2018. Vol. 1, No. 2. P. 91–100.

Liedberg F., Holmberg E., Holmдng S., Ljungberg B., Malmstrцm P.U., Mеnsson W. et al. Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol. 2012. Vol. 46, No. 1. P. 14–18.

Shen J., Liu X., Zhang F.Q., Hu K., Hou X.R. Outcome of three-dimensional conformal radiotherapy for 109 patients with bladder cancer. Chin J Radiat Oncol. 2009. Vol. 18. P. 115–119.

Bauman G., Yartsev S., Rodrigues G., Lewis C., Venkatesan V.M., Yu E. et al. A prospective evaluation of helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007. Vol. 68, No. 2. P. 632–641.

Foroudi F., Wong J., Haworth A., Baille A., McAlpine J., Rolfo A. et al. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. J Med Imaging Radiat Oncol. 2009. Vol. 53, No. 2. P. 226–233.

Foroudi F., Wong J., Kron T., Rolfo A., Haworth A., Roxby P. et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 2011. Vol. 81, No. 3. P. 765–771.

Pos F.J., Hulshof M., Lebesque J., Lotz H., van Tienhoven G., Moonen L. et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2006. Vol. 64, No. 3. P. 862–868.

Koning C.C.E., Blank L.E.C.M., Koedooder C., van Os R.M., van de Kar M., Jansen E. et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol. 2012. Vol. 23, No. 11. P. 2948–2953.

Pos F., Moonen L. Brachytherapy in the treatment of invasive bladder cancer. Semin Radiat Oncol. 2005. Vol. 15, No. 1. P. 49–54.

Pos F., Horenblas S., Dom P., Moonen L., Bartelink H. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys. 2005. Vol. 61, No. 3. P. 678–686.

McDonald F., Lalondrelle S., Taylor H., Warren-Oseni K., Khoo V., McNair H.A. et al. Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin Oncol (R Coll Radiol). 2013. Vol. 25, No. 9. P. 549–556.

Turgeon G.A., Souhami L., Cury F.L., Faria S.L., Duclos M., Sturgeon J. et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014. Vol. 88, No. 2. P. 326–331.

Nowak-Sadzikowska J., Jakubowicz J., Skуra T., PudeBek K. Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome. Contemp Oncol (Pozn). 2013. Vol. 17, No. 3. P. 302–306.

Piet A.H., Hulshof M.C., Pieters B.R., Pos F.J., de Reijke T.M., Koning C.C. Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer. Strahlenther Onkol. 2008. Vol. 184, No. 6. P. 313–318.

Lewanski C.R., Gullick W.J. Radiotherapy and cellular signalling. Lancet Oncol. 2001. Vol. 2, No. 6. P. 366–370.

Velic D., Couturier A.M., Ferreira M.T., Rodrigue A., Poirier G.G., Fleury F. et al. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer. Biomolecules. 2015. Vol. 5, No. 4. P. 3204–3259.

Shao C., Folkard M., Michael B.D., Prise K.M. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci USA. 2004. Vol. 101, No. 37. P. 13495–13500.

Pilones K.A., Vanpouille-Box C., Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015. Vol. 25, No. 1. P. 28–33.

Wang J.S., Wang H.J., Qian H.L. Biological effects of radiation on cancer cells. Mil Med Res. 2018. Vol. 5, No. 1. P. 20.

Mak R.H., Hunt D., Shipley W.U., Efstathiou J.A., Tester W.J., Hagan M.P. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014. Vol. 32, No. 34. P. 3801–3809.

Rodel C., Grabenbauer G.G., Kuhn R., Papadopoulos T., Dunst J., Meyer M. et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002. Vol. 20, No. 14. P. 3061–3071.

Shipley W.U., Kaufman D.S., Zehr E., Heney N.M., Lane S.C., Thakral H.K. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002. Vol. 60, No. 1. P. 62–76.

Coen J.J., Zhang P., Saylor P.J., Lee C.T., Wu C.L., Parker W. et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019. Vol. 37, No. 1. P. 44–51.

Cooke P.W., Dunn J.A., Latief T., Bathers S., James N.D., Wallace D.M. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur Urol. 2000. Vol. 38, No. 3. P. 279–86.

Zhong J., Switchenko J., Jegadeesh N.K., Cassidy R.J., Gillespie T.W., Master V. et al. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. Am J Clin Oncol. 2019. Vol. 42, No. 1. P. 36–41.

Hayter C.R., Paszat L.F., Groome P.A., Schulze K., Math M., Mackillop W.J. A population-based study of the use and outcome of radical radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1999. Vol. 45, No. 5. P. 1239–1245.

Downloads

Published

2021-05-16

Issue

Vol. 25 No. 1 (2021)

Section

Oncourology

License

Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).

Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.